Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
160 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
H1N1 Infection - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'H1N1 Infection - Pipeline Review, H2 2014', provides an overview of the H1N1 Infection's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of H1N1 Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H1N1 Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H1N1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H1N1 Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for H1N1 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 H1N1 Infection Overview 8 Therapeutics Development 9 Pipeline Products for H1N1 Infection - Overview 9 Pipeline Products for H1N1 Infection - Comparative Analysis 10 H1N1 Infection - Therapeutics under Development by Companies 11 H1N1 Infection - Therapeutics under Investigation by Universities/Institutes 15 H1N1 Infection - Pipeline Products Glance 17 Clinical Stage Products 17 Early Stage Products 18 H1N1 Infection - Products under Development by Companies 19 H1N1 Infection - Products under Investigation by Universities/Institutes 21 H1N1 Infection - Companies Involved in Therapeutics Development 22 Johnson & Johnson 22 Kyowa Hakko Kirin Co., Ltd. 23 Autoimmune Technologies, LLC 24 Inovio Pharmaceuticals, Inc. 25 Takeda Pharmaceutical Company Limited 26 CEL-SCI Corporation 27 Sarepta Therapeutics, Inc. 28 Crucell N.V. 29 OPKO Health, Inc. 30 Medicago Inc. 31 NanoViricides, Inc. 32 Medigen Biotechnology Corporation 33 XOMA Corporation 34 Antigen Express, Inc. 35 Colby Pharmaceutical Company 36 Marinomed Biotechnologie GmbH 37 TechnoVax, Inc. 38 AlphaVax, Inc. 39 Vaxin, Inc. 40 EpiVax, Inc. 41 Kineta, Inc. 42 Adamas Pharmaceuticals, Inc. 43 REPLICor Inc. 44 VaxInnate Corporation 45 Etubics Corporation 46 iBio, Inc. 47 Sirnaomics, Inc. 48 Vaxart, Inc. 49 Cilian AG 50 Revivicor, Inc. 51 Beijing Minhai Biotechnology Co., Ltd 52 TaiMed Biologics Inc. 53 Akshaya Bio Inc. 54 Gemmus Pharma Inc. 55 Onxeo SA 56 H1N1 Infection - Therapeutics Assessment 57 Assessment by Monotherapy Products 57 Assessment by Combination Products 58 Assessment by Target 59 Assessment by Mechanism of Action 61 Assessment by Route of Administration 63 Assessment by Molecule Type 65 Drug Profiles 67 influenza [H1N1] (quadrivalent) (virus like particle) vaccine - Drug Profile 67 VX-787 - Drug Profile 69 pandemic influenza vaccine [H1N1] - Drug Profile 70 Pandemic Flu Vaccine - Drug Profile 71 Pandemic Influenza Vaccine [H1N1] - Drug Profile 72 Influenza Vaccine - Drug Profile 73 radavirsen - Drug Profile 75 VAX-128 - Drug Profile 77 VAX-128B - Drug Profile 78 VAX-128C - Drug Profile 79 VXAA-1.1 - Drug Profile 80 LEAPS-H1N1-DC - Drug Profile 81 INO-3510 - Drug Profile 82 INO-3401 - Drug Profile 84 AEA-35p - Drug Profile 85 INO-3605 - Drug Profile 86 INO-3609 - Drug Profile 87 HAC1 vaccine - Drug Profile 88 H1N1 Syncon Universal Influenza Vaccine - Drug Profile 89 Pandemic Flu Vaccine [H1N1] - Drug Profile 90 Flu Vaccine - Drug Profile 91 NVINF-2 - Drug Profile 92 REP-9 - Drug Profile 93 Pandemic Influenza Vaccine - Drug Profile 94 influenza vaccine [H1N1] - Drug Profile 95 STP-702 - Drug Profile 97 Antibody for Influenza - Drug Profile 98 TVX-002 - Drug Profile 99 Influenza VLP Vaccine - Drug Profile 100 iota-carrageenan - Drug Profile 101 TMB-571 - Drug Profile 102 Flufirvitide-3 - Drug Profile 103 H1N1 vaccine (A/Aichi/2/68) - Drug Profile 104 JVRS-100 + Universal Influenza Vaccine - Drug Profile 105 influenza vaccine [H1N1] (Mutivalent) - Drug Profile 106 NVINF-1 - Drug Profile 107 Innate Immune Agonists - Drug Profile 109 BA-032 - Drug Profile 110 CR-9114 - Drug Profile 111 CiFlu - Drug Profile 112 Human Antibody Based Vaccines - Drug Profile 114 Pandemic Influenza Vaccine (H1, H5) - Drug Profile 116 CYM-5442 - Drug Profile 117 influenza A vaccine - Drug Profile 118 Vaccine for Infectious Disease - Drug Profile 119 influenza vaccine [H1N1] - Drug Profile 120 C-05 - Drug Profile 121 Gamma-Flu - Drug Profile 122 VH-244 - Drug Profile 123 GP-1681 - Drug Profile 125 influenza vaccine [H1N1] - Drug Profile 127 Z-3G1 - Drug Profile 128 RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection - Drug Profile 129 GREFLU/CAL - Drug Profile 130 Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile 131 ADS-324 - Drug Profile 132 H1N1 Infection - Recent Pipeline Updates 133 H1N1 Infection - Dormant Projects 145 H1N1 Infection - Product Development Milestones 146 Featured News & Press Releases 146 Appendix 155 Methodology 155 Coverage 155 Secondary Research 155 Primary Research 155 Expert Panel Validation 155 Contact Us 156 Disclaimer 156
List of Tables Number of Products under Development for H1N1 Infection, H2 2014 13 Number of Products under Development for H1N1 Infection - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Development by Companies, H2 2014 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2014 20 Comparative Analysis by Clinical Stage Development, H2 2014 21 Comparative Analysis by Early Stage Development, H2 2014 22 Products under Development by Companies, H2 2014 23 Products under Development by Companies, H2 2014 (Contd..1) 24 Products under Investigation by Universities/Institutes, H2 2014 25 H1N1 Infection - Pipeline by Johnson & Johnson, H2 2014 26 H1N1 Infection - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 27 H1N1 Infection - Pipeline by Autoimmune Technologies, LLC, H2 2014 28 H1N1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 29 H1N1 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 30 H1N1 Infection - Pipeline by CEL-SCI Corporation, H2 2014 31 H1N1 Infection - Pipeline by Sarepta Therapeutics, Inc., H2 2014 32 H1N1 Infection - Pipeline by Crucell N.V., H2 2014 33 H1N1 Infection - Pipeline by OPKO Health, Inc., H2 2014 34 H1N1 Infection - Pipeline by Medicago Inc., H2 2014 35 H1N1 Infection - Pipeline by NanoViricides, Inc., H2 2014 36 H1N1 Infection - Pipeline by Medigen Biotechnology Corporation, H2 2014 37 H1N1 Infection - Pipeline by XOMA Corporation, H2 2014 38 H1N1 Infection - Pipeline by Antigen Express, Inc., H2 2014 39 H1N1 Infection - Pipeline by Colby Pharmaceutical Company, H2 2014 40 H1N1 Infection - Pipeline by Marinomed Biotechnologie GmbH, H2 2014 41 H1N1 Infection - Pipeline by TechnoVax, Inc., H2 2014 42 H1N1 Infection - Pipeline by AlphaVax, Inc., H2 2014 43 H1N1 Infection - Pipeline by Vaxin, Inc., H2 2014 44 H1N1 Infection - Pipeline by EpiVax, Inc., H2 2014 45 H1N1 Infection - Pipeline by Kineta, Inc., H2 2014 46 H1N1 Infection - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 47 H1N1 Infection - Pipeline by REPLICor Inc., H2 2014 48 H1N1 Infection - Pipeline by VaxInnate Corporation, H2 2014 49 H1N1 Infection - Pipeline by Etubics Corporation, H2 2014 50 H1N1 Infection - Pipeline by iBio, Inc., H2 2014 51 H1N1 Infection - Pipeline by Sirnaomics, Inc., H2 2014 52 H1N1 Infection - Pipeline by Vaxart, Inc., H2 2014 53 H1N1 Infection - Pipeline by Cilian AG, H2 2014 54 H1N1 Infection - Pipeline by Revivicor, Inc., H2 2014 55 H1N1 Infection - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 56 H1N1 Infection - Pipeline by TaiMed Biologics Inc., H2 2014 57 H1N1 Infection - Pipeline by Akshaya Bio Inc., H2 2014 58 H1N1 Infection - Pipeline by Gemmus Pharma Inc., H2 2014 59 H1N1 Infection - Pipeline by Onxeo SA, H2 2014 60 Assessment by Monotherapy Products, H2 2014 61 Assessment by Combination Products, H2 2014 62 Number of Products by Stage and Target, H2 2014 64 Number of Products by Stage and Mechanism of Action, H2 2014 66 Number of Products by Stage and Route of Administration, H2 2014 68 Number of Products by Stage and Molecule Type, H2 2014 70 H1N1 Infection Therapeutics - Recent Pipeline Updates, H2 2014 137 H1N1 Infection - Dormant Projects, H2 2014 149
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
